Novavax Inc. jumped in early trading after US regulators fully approved its Covid vaccine, easing investors’ concerns after ...

Nuvaxovid had been available under emergency use authorization but the full approval may allow it to better compete with ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

China on Sunday announced anti-dumping duties as high as 74.9% on imports of POM copolymers, a type of engineering plastic, ...

In its Friday approval letter, the FDA didn’t explain the restrictions although they reflect skepticism about ...

This vaccine did previously have emergency approval by the FDA for use but can now be marketed in the U.S. for use, the ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The Nuvaxovid COVID-19 vaccine was developed in cooperation with Sanofi, which will pay Novavax $175 million in a milestone agreement. Novavax received Food and Drug Administration approval for its ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...